Your browser doesn't support javascript.
loading
Glucose Lowering Treatment Modalities of Type 2 Diabetes Mellitus.
Gökçay Canpolat, Asena; Sahin, Mustafa.
Afiliación
  • Gökçay Canpolat A; Department of Endocrinology and Metabolism, Ankara University School of Medicine, Ankara, Turkey.
  • Sahin M; Department of Endocrinology and Metabolism, Ankara University School of Medicine, Ankara, Turkey. mustafasahin@ankara.edu.tr.
Adv Exp Med Biol ; 1307: 7-27, 2021.
Article en En | MEDLINE | ID: mdl-32200500
ABSTRACT
This chapter gives an overview of present knowledge and clinical aspects of antidiabetic drugs according to the recently available research evidence and clinical expertise.Many agents are acting on eight groups of pathophysiological mechanisms, which is commonly called as "Ominous Octet" by DeFronzo. The muscle, liver and ß-cell, the fat cell, gastrointestinal tract, α-cell, kidney, and brain play essential roles in the development of glucose intolerance in type 2 diabetic individuals (Defronzo, Diabetes 58773-795, 2009).A treatment paradigm shift is seen in the initiation of anti-hyperglycemic agents from old friends (meglitinides or sulphonylürea) to newer agents effecting on GLP-1 RA or SGLT-2 inhibitors. It is mostly about the other protective positive effects of these agents for kidney, heart, etc. Although there are concerns for the long term safety profiles; they are used widely around the World. The delivery of patient-centered care, facilitating medication adherence, the importance of weight loss in obese patients, the importance of co-morbid conditions are the mainstays of selecting the optimal agent.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Inhibidores del Cotransportador de Sodio-Glucosa 2 / Hipoglucemiantes Límite: Humans Idioma: En Revista: Adv Exp Med Biol Año: 2021 Tipo del documento: Article País de afiliación: Turquía

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Inhibidores del Cotransportador de Sodio-Glucosa 2 / Hipoglucemiantes Límite: Humans Idioma: En Revista: Adv Exp Med Biol Año: 2021 Tipo del documento: Article País de afiliación: Turquía
...